Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 70 years old.
- You had a stem cell transplant from a donor (related, unrelated, or half-matched).
- You have severe acute GVHD (grade III or IV) that did not improve with high-dose steroids.
- Your blood counts are stable: neutrophil count above 1,000 and platelet count at least 20,000.
- You can take oral medications and are expected to live more than 8 weeks.
- You are not pregnant or breastfeeding and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether adding remestemcel-L (a type of cell therapy) to the standard drug ruxolitinib can help people with severe graft-versus-host disease (a complication after a stem cell transplant) that hasn't improved with steroids. The goal is to see if it can reduce symptoms and improve outcomes.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.